Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 4, 2014, Pages 459-469

  Samardzic, Jure ^a   Krpan, Miroslav ^a   Skoric, Bosko ^a   Pasalic, Marijan ^a   Petricevic, Mate ^a   Milicic, Davor ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Acute coronary syndrome; Clopidogrel; Outcome; Platelet reactivity; Tailoring therapy

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; BRAIN ISCHEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY STENTING; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PLATELET REACTIVITY; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; VERY ELDERLY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; TRENDS;

ACUTE CORONARY SYNDROME; AGED; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84910124468     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1087-0     Document Type: Article

References (41)

1. Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 32:2999–3054
2. Steg PG, James SK, Atar D et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619
3. O’Gara PT, Kushner FG, Ascheim DD et al (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 127:e362–e425
4. Jneid H, Anderson JL, Wright RS et al (2012) 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infaction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 126:875–910
5. Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502
6. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246–251
7. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 357:2001–2015
8. Top 20 global products 2012 (2013) IMS Health Midas. http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/Top_20_Global_Products_2012_2.pdf. Accessed 19 October 2013
9. Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057
10. Stone GW, Witzenbichler B, Weisz G et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614–623
11. Aradi D, Storey RF, Komócsi A et al (2014) Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 35:209–215
12. Tantry US, Bonello L, Aradi D et al (2013) Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding. J Am Coll Cardiol 62:2261–2273
13. Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the BleedingAcademic Research Consortium. Circulation 123:2736–2747
14. Sibbing D, Braun S, Morath T et al (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53:849–856
15. Sibbing D, Schulz S, Braun S et al (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8:250–256
16. Yusuf S, Mehta SR, Zhao F et al (2003) Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107:966–972
17. Hazarbasanov D, Velchev V, Finkov B et al (2012) Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis 34:85–90
18. Giles H, Smith REA, Martin J (1994) Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 24:69–72
19. Gawaz M, Neumann FJ, Ott I et al (1996) Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93:229–237
20. Muller I, Seyfarth M, Rudiger S et al (2001) Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85:92–93
21. Breet NJ, van Werkum JW, Bouman HJ et al (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303:754–762
22. Trenk D, Hochholzer W, Fromm MF et al (2008) Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925–1934
23. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS (2009) Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 103:1339–1343
24. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516
25. Lev EI, Patel RT, Maresh KJ et al (2006) Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47:27–33
26. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430–2435
27. Cuisset T, Frere C, Quilici J et al (2009) Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 123:597–603
28. Kuchulakanti PK, Chu WW, Torguson R et al (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113:1108–1113
29. Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105
30. Collet JP, Cuisset T, Rangé G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109
31. Campo G, Parrinello G, Ferraresi P et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:2474–2483
32. Parodi G, Marcucci R, Valenti R et al (2011) High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306:1215–1223
33. Brar SS, ten Berg J, Marcucci M et al (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58:1945–1954
34. Aradi D, Pinter T, Magyari B et al (2014) Optimizing P2Y12-receptor inhibition in acute coronary syndrome after PCI using platelet function testing: impact of prasugrel versus high-dose clopidogrel. J Am Coll Cardiol 63:1061–1070
35. Arméro S, Camoin Jau L, Omar Aït Mokhtar O et al (2010) Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets 21:503–507
36. Gurbel PA, Bliden KP, Hayes KM et al (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45:1392–1396
37. Mayer K, Schulz S, Bernlochner I et al. (2014) A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb Haemost 10;112(2)
38. Siller-Matula JM, Francesconi M, Dechant C et al (2013) Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 167:2018–2023
39. Gurbel PA, Erlinge D, Ohman EM et al (2012) Platelet function during extended prasugrel and Clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 308:1785–1794
40. Bonello L, Camoin-Jau L, Armero S et al (2009) Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 103:5–10
41. Chirumamilla AP, Maehara A, Mintz GS et al (2012) High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging 5:540–549